Movement Control Exercises With and Without Specific Breathing Techniques for the Treatment of Chronic Low Back Pain

March 7, 2023 updated by: Jani Mikkonen, Kuopio University Hospital

Movement Control Exercises With and Without Specific Breathing Techniques for the Treatment of Chronic Low Back Pain: an Open-label Feasibility Study With 2-month

Chronic low back pain (CLBP) is a leading disability globally. Exercise therapies are one of the most commonly prescribed treatment options for CLBP. Specific breathing techniques have been shown to enhance brain-based pain modulation and autonomic nervous system balance; these changes have been shown to improve clinical effectiveness in terms of pain management and psychological factors compared to general exercise. However, no previous studies have added a specific breathing technique protocol to an evidence-based exercise program for CLBP.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00100
        • Private Clinic of principal investigator

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18-68-years-old
  • Low back pain lasting more than 3 months (pain sensation more than 3 days per week)
  • A numerical pain scale of more than 3
  • ≥ 2/6 positive low back movement control tests (as described by Luomajoki et al.)
  • Roland-Morris Disability Questionnaire score of five or greater
  • Who are physically able to perform movement control tests and provide written informed consent.

Exclusion Criteria:

  • Any history of malignant cancer
  • Neurological disease affecting the central nervous system (MS, dementia)
  • Rheumatic disease (fibromyalgia, ankylosing spondylitis/rheumatoid arthritis)
  • Chronic obstructive pulmonary disease,
  • Spinal surgery in the last 12 months
  • A cardiac pacemaker
  • Signs and symptoms of nerve root pathology during the clinic visits.
  • Women who become pregnant during the data collection will also be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Movement control exercise with specific breathing techniques
Movement control exercise with specific breathing techniques (experimental group)
Movement control exercise with or without specific breathing techniques
Active Comparator: Movement control exercise without specific breathing techniques
Movement control exercise without specific breathing techniques (control group)
Movement control exercise with or without specific breathing techniques

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The numerical pain rating scale (NRPS)
Time Frame: Change from Baseline The numerical pain rating scale at 2 months
Eleven-point numerical pain scale. Scale from 0 (no pain) to 10 (worst imaginable)
Change from Baseline The numerical pain rating scale at 2 months
Well-Being in Pain Questionnaire
Time Frame: Change from Baseline Well-Being in Pain Questionnaire at 2 months
Self-developed questionnaire to screen the effects of pain on a person's biopsychosocial well-being. Scale from 0 (no subjective well-being in pain) to 60 (maximum subjective well-being in pain)
Change from Baseline Well-Being in Pain Questionnaire at 2 months
The Roland Morris Disability Questionnaire (RMDQ)
Time Frame: Change from Baseline The Roland Morris Disability Questionnaire at 2 months
Questionnaire measuring disability in chronic low back pain populations. Scale from 0 (no disability) to 24 (maximum low back pain related disability)
Change from Baseline The Roland Morris Disability Questionnaire at 2 months
Central Sensitization Inventory (CSI)
Time Frame: Change from Baseline Central Sensitization Inventory at two months
Screening of central sensitization phenomenon. Scale from 0 (no central sensitization) to 100 (worst imaginable central sensitization)
Change from Baseline Central Sensitization Inventory at two months
The 5-level EQ-5D version of the EuroQol
Time Frame: Change from Baseline The 5-level EQ-5D version of the EuroQol at 2 months
Health status. Scale from 0 (dead) to 1 (full health)
Change from Baseline The 5-level EQ-5D version of the EuroQol at 2 months
The Generalised Anxiety Disorder Assessment (GAD-7)
Time Frame: Change from Baseline The Generalised Anxiety Disorder Assessment at two months
Measure of generalised anxiety disorder related symptoms. Scale from 0 (the most minimal anxiety) to 21 (the most severe anxiety)
Change from Baseline The Generalised Anxiety Disorder Assessment at two months
The Tampa Scale of Kinesiophobia (TSK)
Time Frame: Change from Baseline The Tampa scale of Kinesiophobia at two months
Assessment of subjective kinesiophobia (fear of movement). Scale from 17 (the minimal kinesophobia) to 68 (the most maximum kinesiophobia).
Change from Baseline The Tampa scale of Kinesiophobia at two months
The Pain Catastrophizing Scale (PCS)
Time Frame: Change from Baseline he Pain Catastrophizing Scale at two months
Assessment of catastrophizing (tendency to magnify the threat value of a pain stimulus) related to pain. Scale from 0 (no catastrophizing thoughts) to 52 (maximum catastrophizing thoughts)
Change from Baseline he Pain Catastrophizing Scale at two months
The Pain and Sleep Questionnaire Three-Item Index (PSQ-3)
Time Frame: Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months
Effect of pain on sleep. Scale from 0 (pain have no any effect on sleep) to 30 (pain have maximum effect on sleep)
Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months
The Pain Self-Efficacy Questionnaire (PSEQ)
Time Frame: Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months
assess the self-efficacy of people in pain have in daily activities. The scale is from 0 points (not at all confident) to 6 points (completely confident).
Change from Baseline The Pain and Sleep Questionnaire Three-Item Index at two months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of intervention protocol, recruitment and enrollment
Time Frame: Through study completion, an average of 2 mothns
To assess the feasibility of the intervention protocol and subject recruitment and enrollment.
Through study completion, an average of 2 mothns
Responsiveness
Time Frame: Through study completion, an average of 2 months
To quantify the changes in and determine the responsiveness of the outcome measures, in order to calculate the sample size for a randomized controlled trial (RCT) based on the chosen primary outcome measure(s).
Through study completion, an average of 2 months
Quantifying
Time Frame: Through study completion, an average of 2 months
To quantify the changes in self-adherence levels to home exercise and monitor possible pain medication usage, and side effects, adverse events and injuries during exercise.
Through study completion, an average of 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2022

Primary Completion (Actual)

November 14, 2022

Study Completion (Actual)

November 14, 2022

Study Registration Dates

First Submitted

February 8, 2022

First Submitted That Met QC Criteria

February 24, 2022

First Posted (Actual)

March 7, 2022

Study Record Updates

Last Update Posted (Estimate)

March 9, 2023

Last Update Submitted That Met QC Criteria

March 7, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KuopioUH_2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Low-back Pain

Clinical Trials on Home exercise

Subscribe